10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Completed
Memorial Sloan Kettering Cancer Center
Phase 1/Phase 2
2002-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in
treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's
lymphoma.
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2002-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in
treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's
lymphoma.
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Completed
Spectrum Pharmaceuticals, Inc
Phase 1/Phase 2
2002-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in
treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's
lymphoma.
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Completed
Acrotech Biopharma LLC
Phase 1/Phase 2
2007-05-01
This study is for patients with lymphoproliferative malignancies that have progressed after
receiving a previous treatment (relapsed) or are no longer responding to treatment
(refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma
(HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's
macroglobulinemia.
This study is being done to find doses of the combination of pralatrexate and gemcitabine
with vitamin B12 and folic acid that can be safely given to patients with these types of
lymphoma and explore the effectiveness of the treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
